var data={"title":"Fluorouracil (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluorouracil (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389590?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluorouracil-systemic-drug-information\" class=\"drug drug_general\">see &quot;Fluorouracil (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=fluorouracil-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluorouracil (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100806\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adrucil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22873127\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fluorouracil Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493258\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493685\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluorouracil-systemic-drug-information\" class=\"drug drug_general\">see &quot;Fluorouracil (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose, frequency, number of doses, and/or start date may vary by protocol and treatment phase. Refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatoblastoma:</b> Limited data available: Infants, Children, and Adolescents: IV: 600 mg/m<sup>2</sup>/dose every 3 weeks on day 2 or 3 (in combination with cisplatin, vincristine &plusmn; doxorubicin) (Douglass 1993; Ortega 2000; Watanabe 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasopharyngeal carcinoma:</b> Limited data available: Children &ge;8 years and Adolescents: Continuous IV infusion: 1,000 mg/m<sup>2</sup>/day for 3 to 5 days every 3 to 4 weeks for 3 to 4 cycles (in combination with other chemotherapy agents) (Buehrlen 2012; Casanova 2012; Mertens 2005; Rodriguez-Galindo 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012). Details concerning dosing in combination regimens should be consulted:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer:</b> IV: 500 or 600 mg/m<sup>2</sup> on days 1 and 8; frequency and combinations of other chemotherapeutics protocol specific; refer to individual protocols (Assikis 2003; Goldhirsch 1998; Levine 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Colorectal cancer:</b> IV: Refer to individual protocol for specific dosing and frequency information.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">500 mg/m<sup>2</sup> bolus (in combination with leucovorin with/without oxaliplatin) (Haller 2005; Kuebler 2007) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">400 mg/m<sup>2</sup> bolus followed by 1,200 mg/m<sup>2</sup>/day continuous infusion for 2 days (Andr&eacute; 1999; Cheeseman 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastric cancer:</b> IV: 750 to 1,000 mg/m<sup>2</sup>/day continuous IV infusion for 4 to 5 days (in combination with other chemotherapy agents) (Ajani 2007; Bang 2010; Tepper 2008; Van Cutsem 2006) <b>or</b> 200 mg/m<sup>2</sup>/day continuous IV infusion days 1 to 21 (in combination with other chemotherapy agents) (Cunningham 2006; Sumpter 2005); refer to individual protocol for specific dosing and frequency information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pancreatic cancer:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chemoradiation therapy:</i> 250 mg/m<sup>2</sup>/day continuous infusion for 3 weeks prior to and then throughout radiation therapy (Regine 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Fluorouracil-Leucovorin:</i> 425 mg/m<sup>2</sup>/day (bolus) days 1 to 5 every 28 days (in combination with leucovorin) for 6 cycles (Neoptolemos 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>FOLFIRINOX regimen:</i> 400 mg/m<sup>2</sup> bolus on day 1, followed by 1,200 mg/m<sup>2</sup>/day continuous infusion for 2 days (over 46 hours) every 14 days (in combination with leucovorin, irinotecan, and oxaliplatin) until disease progression or unacceptable toxicity for a recommended 12 cycles (Conroy 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adult: There are no dosage adjustments provided in the manufacturer's labeling; however, extreme caution should be used in patients with renal impairment. The following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;50 mL/minute and continuous renal replacement therapy (CRRT): No dosage adjustment necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Administer standard dose following hemodialysis on dialysis days (Janus 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Administer 50% of standard dose following hemodialysis (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adult: There are no dosage adjustments provided in the manufacturer's labeling; however, extreme caution should be used in patients with hepatic impairment. The following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment (degree not specified): Administer &lt;50% of dose, then increase if toxicity does not occur (Koren 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bilirubin &gt;5 mg/dL: Avoid use (Floyd 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100923\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adrucil: 500 mg/10 mL (10 mL); 2.5 g/50 mL (50 mL); 5 g/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/10 mL (10 mL); 1 g/20 mL (20 mL); 2.5 g/50 mL (50 mL); 5 g/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 g/50 mL (50 mL); 5 g/100 mL (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100809\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493686\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">IV: Administration rate varies by protocol; refer to specific reference for protocol. May be administered undiluted by IV push, or further diluted in appropriate fluids and administered by IV bolus, or as a continuous infusion. Avoid extravasation (may be an irritant).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132596\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100857\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not freeze. Protect from light. Pharmacy bulk vials should be used within 4 hours of initial entry. Syringes and solutions diluted for infusion may be stored for up to 4 hours (at room temperature) prior to administration (according to the manufacturer). Fluorouracil 50 mg/mL in NS was stable in polypropylene infusion pump syringes for 7 days when stored at 30&deg;C (86&deg;F) (Stiles 1996). Stability of fluorouracil 1 mg/mL or 10 mg/mL in NS or D5W in PVC bags was demonstrated for up to 14 days at 4&deg;C (39.2&deg;F) and 21&deg;C (69.8&deg;F) (Martel 1996). Stability of undiluted fluorouracil (50 mg/mL) in ethylene-vinyl acetate ambulatory pump reservoirs was demonstrated for 3 days at 4&deg;C (39.2&deg;F) (precipitate formed after 3 days) and for 14 days at 33&deg;C (91.4&deg;F) (Martel 1996). Stability of undiluted fluorouracil (50 mg/mL) in PVC ambulatory pump reservoirs was demonstrated for 5 days at 4&deg;C (39.2&deg;F) (precipitate formed after 5 days) and for 14 days at 33&deg;C (91.4&deg;F) (Martel 1996). Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493260\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of carcinoma of stomach (gastric), colon, rectum, breast, and pancreas (FDA approved in adults); has also been used for the treatment of hepatoblastoma, nasopharyngeal carcinoma, head and neck cancer, bladder cancer, and cervical cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100786\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fluorouracil may be confused with floxuridine, flucytosine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Continuous infusion:  Serious errors have occurred when doses administered by continuous ambulatory infusion pumps have inadvertently been given over 1 to 4 hours instead of the intended extended continuous infusion duration. Depending on protocol, infusion duration may range from 46 hours to 7 days for fluorouracil continuous infusions. Ambulatory pumps utilized for continuous infusions should have safeguards to allow for detection of programming errors. If using an elastomeric device for ambulatory continuous infusion, carefully select the device and double check the flow rate. Appropriate prescribing (in single daily doses [not course doses] with instructions to infuse over a specific time period), appropriate training/certification/education of staff involved with dispensing and administration processes, and independent double checks should be utilized throughout dispensing and administration procedures.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100836\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Toxicity depends on duration of treatment and/or rate of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiac failure, cerebrovascular accident, ischemic heart disease, local thrombophlebitis, myocardial infarction, vasospasm, ventricular ectopy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebellar syndrome (acute), confusion, disorientation, euphoria, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, changes in nails (including nail loss), dermatitis, hyperpigmentation (supravenous), maculopapular rash (pruritic), palmar-plantar erythrodysesthesia, skin fissure, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, diarrhea, esophagopharyngitis, gastrointestinal hemorrhage, gastrointestinal ulcer, mesenteric ischemia (acute), nausea, stomatitis, tissue sloughing (gastrointestinal), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, leukopenia (nadir: days 9 to 14; recovery by day 30), pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (generalized)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Lacrimal stenosis, lacrimation, nystagmus, photophobia, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Dysgeusia (Syed 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100831\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Known hypersensitivity to fluorouracil or any component of the formulation; debilitated patients; poor nutritional state; depressed bone marrow function following radiotherapy or therapy with other antineoplastic agents; potentially serious infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100832\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Fluorouracil can cause severe and fatal hematologic toxicity (neutropenia, thrombocytopenia, and anemia). The neutrophil nadir usually occurs between 9 to 14 days after administration. Monitor blood counts prior to each treatment cycle, weekly if administered on a weekly or similar schedule, and as clinically indicated. Withhold fluorouracil for grade 4 hematologic toxicity; when blood counts resolve to grade 1 or lower, resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiotoxicity: Based on postmarketing reports, fluorouracil may cause cardiotoxicity (angina, MI/ischemia, arrhythmia, and heart failure). Risk factors for cardiotoxicity include continuous infusion administration (versus IV bolus) and coronary artery disease. Withhold fluorouracil for cardiotoxicity. The risks of resuming fluorouracil in patients with resolved cardiotoxicity have not been established. In a scientific statement from the AHA, fluorouracil has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Fluorouracil is associated with severe diarrhea. Withhold treatment for grade 3 or 4 diarrhea until resolved or to grade 1 or lower, then resume fluorouracil at a reduced dose. Administer fluids, electrolyte replacement, and/or antidiarrheal treatments as necessary. Mucositis, stomatitis, or esophagopharyngitis (which may lead to mucosal sloughing or ulceration) may occur with fluorouracil. The incidence of mucositis is reported to be higher with IV bolus fluorouracil administration (vs continuous infusion). Withhold fluorouracil grade 3 or 4 mucositis; resume at a reduced dose once mucositis has resolved to grade 1 or lower.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hand-foot syndrome: Fluorouracil is associated with palmar-plantar erythrodysesthesia (hand-foot syndrome; HFS). Symptoms of HFS include a tingling sensation, pain, swelling, erythema with tenderness, and desquamation. HFS occurs more commonly when fluorouracil is administered as a continuous infusion (compared to IV bolus) and has been reported to occur more frequently in patients with prior chemotherapy exposure. The onset of HFS is usually after 8 to 9 weeks of fluorouracil, although may occur earlier. Initiate supportive care for symptomatic relief of HFS. Withhold fluorouracil for grade 2 or 3 HFS; resume at a reduced dose when HFS has resolved to grade 1 or lower.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperammonemic encephalopathy: Fluorouracil may result in hyperammonemic encephalopathy in the absence of liver disease or other identifiable cause (postmarketing reports). The onset of hyperammonemic encephalopathy signs/symptoms (altered mental status, confusion, disorientation, coma, or ataxia, in the presence of concomitant elevated serum ammonia level) was within 72 hours after fluorouracil infusion initiation. Withhold fluorouracil for hyperammonemic encephalopathy and initiate ammonia-lowering therapy. The risks of resuming fluorouracil in patients with resolved hyperammonemic encephalopathy have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Fluorouracil may cause neurologic toxicity, including acute cerebellar syndrome and other neurologic events (postmarketing reports). Neurologic symptoms included confusion, disorientation, ataxia, or visual disturbances. Withhold fluorouracil for neurologic toxicity. There are insufficient data on the risks of resuming fluorouracil in patients with resolved neurologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dihydropyrimidine dehydrogenase deficiency: Patients with select homozygous or compound heterozygous dihydropyrimidine dehydrogenase (DPD) gene mutations that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions (eg, mucositis, diarrhea, neutropenia, neurotoxicity) due to fluorouracil. Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions when administered fluorouracil. Based on clinical assessment of toxicity onset, duration, and severity, withhold or permanently discontinue fluorouracil in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. There is no fluorouracil dose that has been proven safe in patients with complete absence of DPD activity and data are insufficient to recommend a specific dose in patients with partial DPD activity as measured by any specific test.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Warfarin: Clinically significant coagulation parameter elevations have been reported with concomitant use of warfarin and fluorouracil. Closely monitor INR and prothrombin time in patients receiving concomitant coumarin-derivative anticoagulants such as warfarin and adjust the anticoagulant dose accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration safety issues: Serious errors have occurred when doses administered by continuous ambulatory infusion pumps have inadvertently been given over 1 to 4 hours instead of the intended extended continuous infusion duration. Depending on protocol, infusion duration may range from 46 hours to 7 days for fluorouracil continuous infusions. Ambulatory pumps utilized for continuous infusions should have safeguards to allow for detection of programming errors. If using an elastomeric device for ambulatory continuous infusion, carefully select the device and double check the flow rate. Appropriate prescribing (in single daily doses [not course doses] with instructions to infuse over a specific time period), appropriate training/certification/education of staff involved with dispensing and administration processes, and independent double checks should be utilized throughout dispensing and administration procedures (ISMP [Smetzer 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antidote: Uridine triacetate (formerly called vistonuridine), has been studied in cases of fluorouracil overdose. In a clinical study of 98 patients who received uridine triacetate for fluorouracil toxicity (due to overdose, accidental capecitabine ingestion, or possible DPD deficiency), 96 patients recovered fully (Bamat 2013). Of 17 patients receiving uridine triacetate beginning within 8 to 96 hours after fluorouracil overdose, all patients fully recovered (von Borstel 2009). Refer to Uridine Triacetate monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9844112\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100851\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15990&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP2C9 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP2C9 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Fluorouracil (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Fluorouracil (Systemic) may increase the serum concentration of Fosphenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemcitabine: May increase the serum concentration of Fluorouracil (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gimeracil: May increase the serum concentration of Fluorouracil (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May increase the serum concentration of Fluorouracil (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Fluorouracil (Systemic) may increase the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: May decrease the serum concentration of Fluorouracil (Systemic). SORAfenib may increase the serum concentration of Fluorouracil (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fluorouracil (Systemic) may increase the serum concentration of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100827\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100828\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects (increased resorptions, embryolethality, and teratogenicity) have been observed in animal reproduction studies. Based on the mechanism of action, fluorouracil may cause fetal harm if administered during pregnancy (according to the manufacturer&rsquo;s labeling). Females of reproductive potential and male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months following cessation of fluorouracil therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chemotherapy, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen (common regimens administered during pregnancy include doxorubicin [or epirubicin], cyclophosphamide, and fluorouracil); chemotherapy should not be administered during the first trimester, after 35 weeks' gestation, or within 3 weeks of planned delivery (Amant 2010; Loibl 2006). The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (Peccatori 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Fertility (male and female) may be impaired during fluorouracil treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493687\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, renal function tests, liver function tests; signs of palmar-plantar erythrodysesthesia syndrome, stomatitis, diarrhea, hemorrhage, or gastrointestinal ulcers or bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100861\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fluorouracil is a pyrimidine analog antimetabolite that interferes with DNA and RNA synthesis; after activation, F-UMP (an active metabolite) is incorporated into RNA to replace uracil and inhibit cell growth; the active metabolite F-dUMP, inhibits thymidylate synthetase, depleting thymidine triphosphate (a necessary component of DNA synthesis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100876\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Fluorouracil distributes throughout the body, including brain tissue, CSF, bone marrow, intestinal mucosa, and liver.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; via a dehydrogenase enzyme; FU must be metabolized to form active metabolites, 5-fluoroxyuridine monophosphate (F-UMP) and 5-5-fluoro-2&rsquo;-deoxyuridine-5&rsquo;-O-monophosphate (F-dUMP)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Following bolus infusion: 8 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (5% to 20% as unchanged drug within 6 hours; metabolites over 3 to 4 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100925\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Adrucil Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 gm/50 mL (50 mL): $23.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $39.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/10 mL (10 mL): $6.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluorouracil Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/20 mL (20 mL): $6.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 gm/50 mL (50 mL): $30.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $61.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/10 mL (10 mL): $3.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961974\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>5-Fluril (BD);</li>\n      <li>5-FU (DE, JP, KR);</li>\n      <li>Agicil (MT);</li>\n      <li>Biluracil (VN);</li>\n      <li>Curacil (ID);</li>\n      <li>Fivoflu (IN, JO, PH, VE, ZW);</li>\n      <li>Flonida (IN);</li>\n      <li>Fluonco (PH);</li>\n      <li>Flurablastin (DK, FI, NO, SE);</li>\n      <li>Fluracedyl (BE, MY, NL, PH);</li>\n      <li>Fluroblastin (VE);</li>\n      <li>Fluroblastine (BE);</li>\n      <li>Fluroxan (BD, LK);</li>\n      <li>Ftorolik (UA);</li>\n      <li>Fu Ke (CN);</li>\n      <li>La-Fu (CZ);</li>\n      <li>Pharmauracil (PK);</li>\n      <li>Raciwel (LK);</li>\n      <li>Ribofluor (DE);</li>\n      <li>Sinofuan Implant (CN);</li>\n      <li>Triosules (AR);</li>\n      <li>Utoral (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adrucil (fluouracil) [prescribing information]. Irvine, CA: Teva Parenteral Medicines, Inc; July 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ajani JA, Moiseyenko VM, Tjulandin S, et al, &quot;Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group,&quot; <i>J Clin Oncol</i>, 2007, 25(22):3210-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17664468/pubmed\" target=\"_blank\" id=\"17664468\">17664468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andr&eacute; T, Louvet C, Maindrault-Goebel F, et al, &quot;CPT-11 (Irinotecan) Addition to Bimonthly, High-Dose Leucovorin and Bolus and Continuous-Infusion 5-Fluorouracil (FOLFIRI) for Pretreated Metastatic Colorectal Cancer. GERCOR,&quot; <i>Eur J Cancer</i>, 1999, 35(9):1343-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/10658525/pubmed\" target=\"_blank\" id=\"10658525\">10658525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Assikis V, Buzdar A, Yang Y, et al, &ldquo;A Phase III Trial of Sequential Adjuvant Chemotherapy for Operable Breast Carcinoma: Final Analysis With 10-Year Follow-Up,&rdquo; <i>Cancer</i>, 2003, 97(11):2716-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/12767083/pubmed\" target=\"_blank\" id=\"12767083\">12767083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balis FM, Holcenberg JS and Bleyer WA, &ldquo;Clinical Pharmacokinetics of Commonly Used Anticancer Drugs,&rdquo; <i>Clin Pharmacokinet</i>, 1983, 8(3):202-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/6189661 /pubmed\" target=\"_blank\" id=\"6189661 \">6189661 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bamat MK, Tremmel R, von Borstel R, et al. Clinical experience with uridine triacetate for 5-FU overexposure: an update [abstract e20592 from 2013 ASCO Annual Meeting]. <i>J Clin Oncol</i>. 2013;31(18s):e20592.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bang YJ, Van Cutsem E, Feyereislova A, et al, &quot;Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial,&quot; <i>Lancet</i>, 2010, 376(9742):687-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20728210/pubmed\" target=\"_blank\" id=\"20728210\">20728210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buehrlen M, Zwaan CM, Granzen B, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. <i>Cancer</i>. 2012;118(19):4892-4900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22359313/pubmed\" target=\"_blank\" id=\"22359313\">22359313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casanova M, Bisogno G, Gandola L, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. <i>Cancer</i>. 2012;118(10):2718-2725.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21918965/pubmed\" target=\"_blank\" id=\"21918965\">21918965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheeseman SL, Joel SP, Chester JD, et al, &ldquo;A &lsquo;Modified de Gramont&rsquo; Regimen of Fluorouracil, Alone and With Oxaliplatin, for Advanced Colorectal Cancer,&rdquo; <i>Br J Cancer</i>, 2002, 87(4):393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/12177775/pubmed\" target=\"_blank\" id=\"12177775\">12177775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conroy T, Desseigne F, Ychou M, et al, &ldquo;FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer,&rdquo; <i>N Engl J Med</i>, 2011, 364(19):1817-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21561347/pubmed\" target=\"_blank\" id=\"21561347\">21561347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham D, Allum WH, Stenning SP, et al, &quot;Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer,&quot; <i>N Engl J Med</i>, 2006, 355(1):11-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/16822992/pubmed\" target=\"_blank\" id=\"16822992\">16822992</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. <i>J Clin Oncol</i>. 1993;11(1):96-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8380296/pubmed\" target=\"_blank\" id=\"8380296\">8380296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluouracil [prescribing information]. Ahmedabad, Gujurat, India: Intas Pharmaceuticals Ltd; March 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldhirsch A, Colleoni M, Coates AS, et al, &ldquo;Adding Adjuvant CMF Chemotherapy to Either Radiotherapy or Tamoxifen: Are All CMFs Alike? The International Breast Cancer Study Group (IBCSG),&rdquo; <i>Ann Oncol</i>, 1998, 9(5):489-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/9653488/pubmed\" target=\"_blank\" id=\"9653488\">9653488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haller DG, Catalano PJ, Macdonald JS, et al, &ldquo;Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089,&rdquo; <i>J Clin Oncol</i>, 2005, 23(34):8671-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/16314627/pubmed\" target=\"_blank\" id=\"16314627\">16314627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in the healthcare settings 2016. Available at <a href=\"https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf\" target=\"_blank\">https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al, &quot;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&quot; <i>Ann Oncol</i>, 2010, 21(7):1395-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo; <i>Ann Pharmacother</i>, 1992,  26(3):363-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/1554959/pubmed\" target=\"_blank\" id=\"1554959\">1554959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuebler JP, Wieand HS, O'Connell MJ, et al, &ldquo;Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07,&rdquo; <i>J Clin Oncol</i>, 2007, 25(16):2198-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17470851/pubmed\" target=\"_blank\" id=\"17470851\">17470851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine MN, Bramwell VH, Pritchard KI, et al, &ldquo;Randomized Trial of Intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy Compared With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer, National Cancer Institute of Canada Clinical Trials Group,&rdquo; <i>J Clin Oncol</i>, 1998, 16(8):2651-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/9704715 /pubmed\" target=\"_blank\" id=\"9704715 \">9704715 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. <i>J Pharm Biomed Anal</i>. 1996;14(4):395-399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8729637/pubmed\" target=\"_blank\" id=\"8729637\">8729637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mertens R, Granzen B, Lassay L, et al. Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH). <i>Cancer</i>. 2005;104(5):1083-1089.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15999363/pubmed\" target=\"_blank\" id=\"15999363\">15999363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Gastric Cancer,&rdquo; Version 2.2012. Available at http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neoptolemos JP, Stocken DD, Bassi C, et al, &ldquo;Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid Vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2010, 304(10):1073-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20823433/pubmed\" target=\"_blank\" id=\"20823433\">20823433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega JA, Douglass EC, Feusner JH, et al, &quot;Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report From the Children's Cancer Group and the Pediatric Oncology Group,&quot; <i>J Clin Oncol</i>, 2000, 18(14):2665-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/10894865/pubmed\" target=\"_blank\" id=\"10894865\">10894865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27400984\"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regine WF, Winter KA, Abrams RA, et al, &ldquo;Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial,&rdquo; <i>JAMA,</i> 2008, 299(9):1019-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18319412/pubmed\" target=\"_blank\" id=\"18319412\">18319412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez-Galindo C, Wofford M, Castleberry RP, et al, &quot;Preradiation Chemotherapy With Methotrexate, Cisplatin, 5-Fluorouracil, and Leucovorin for Pediatric Nasopharyngeal Carcinoma,&quot; <i>Cancer</i>, 2005, 103(4):850-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15641027/pubmed\" target=\"_blank\" id=\"15641027\">15641027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetzer J, Cohen M, eds. Accidental overdoses involving fluorouracil infusions. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2015;20(12):1-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiles ML, Allen LV, and Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. <i>Am J Health Syst Pharm</i>. 1996;53(13):1583-1588.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8809281/pubmed\" target=\"_blank\" id=\"8809281\">8809281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sumpter K, Harper-Wynne C, Cunningham D, et al, &ldquo;Report of Two Protocol Planned Interim Analyses in a Randomized Multicenter Phase III Study Comparing Capecitabine With Fluorouracil and Oxaliplatin With Cisplatin in Patients With Advanced Oesophagogastric Cancer Receiving ECF,&rdquo; <i>Br J Cancer</i>, 2005, 92(11):1976-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15928658/pubmed\" target=\"_blank\" id=\"15928658\">15928658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepper J, Krasna MJ, Niedzwiecki D, et al, &quot;Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781,&quot; <i>J Clin Oncol</i>, 2008, 26(7):1086-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18309943/pubmed\" target=\"_blank\" id=\"18309943\">18309943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Cutsem E, Moiseyenko VM, Tjulandin S, et al, &quot;Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group,&rdquo; <i>J Clin Oncol</i>, 2006, 24(31):4991-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17075117/pubmed\" target=\"_blank\" id=\"17075117\">17075117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Borstel R, O&rsquo;Neil J, Bamat M. Vistonuridine: an orally administered, life-saving antidote for 5-fluorouracil (5FU) overdose. <i>J Clin Oncol</i>. 2009;27(15S):9616 [abstract 9616 from 2009 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watanabe K. Current chemotherapeutic approaches for hepatoblastoma. <i>Int J Clin Oncol</i>. 2013;18(6):955-961.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24052132/pubmed\" target=\"_blank\" id=\"24052132\">24052132</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15990 Version 152.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8100806\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F22873127\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10493258\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10493685\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8100923\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8100809\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10493686\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132596\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8100857\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10493260\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8100786\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8100836\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8100831\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8100832\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9844112\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8100851\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8100827\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8100828\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10493687\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8100861\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8100876\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8100925\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961974\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15990|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluorouracil-systemic-drug-information\" class=\"drug drug_general\">Fluorouracil (systemic): Drug information</a></li><li><a href=\"topic.htm?path=fluorouracil-systemic-patient-drug-information\" class=\"drug drug_patient\">Fluorouracil (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}